Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
F340883-1mg | 1mg | In stock | $21.90 | |
F340883-5mg | 5mg | In stock | $90.90 | |
F340883-10mg | 10mg | In stock | $142.90 | |
F340883-25mg | 25mg | In stock | $321.90 | |
F340883-50mg | 50mg | In stock | $521.90 | |
F340883-100mg | 100mg | In stock | $848.90 |
a cell-permeable, PLD1/2 inhibitor
Synonyms | FIPI|939055-18-2|FIPI free base|5-Fluoro-2-indolyl deschlorohalopemide|5-fluoro-N-[2-[4-(2-oxo-3H-benzimidazol-1-yl)piperidin-1-yl]ethyl]-1H-indole-2-carboxamide|5-Fluoro-N-(2-(4-(2-Oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidin-1-yl)ethyl)-1H-indole- |
---|---|
Specifications & Purity | Moligand™, ≥98% |
Storage Temp | Store at -20°C |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Action Type | INHIBITOR |
Mechanism of action | Inhibitor of PLD1;Inhibitor of PLD2 |
Product Description | FIPI is a cell-permeable, PC-PLD1/2 (PLD1/2) inhibitor (IC|50|= 1 nM and 10 nM for PLD1 and PLD2, respectively, in a CHO cell based assay, and IC|50|= 20 nM for PLD2 in a biochemical assay), that displays no activity toward MitoPLD, and is selective for PLD1 and PLD2 over other PLD superfamily enzymes. FIPI is also shown to block PLD2-dependent effects on cytoskeletal reorganization and cell trafficking in CHO cells, and diminish fMLP-directed neutrophil chemotaxis in HL60 cells at 750 nM. |
pKa | pKa: 12.04 (Predicted), pKa: 8.53 (Predicted) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
IUPAC Name | 5-fluoro-N-[2-[4-(2-oxo-3H-benzimidazol-1-yl)piperidin-1-yl]ethyl]-1H-indole-2-carboxamide |
---|---|
INCHI | InChI=1S/C23H24FN5O2/c24-16-5-6-18-15(13-16)14-20(26-18)22(30)25-9-12-28-10-7-17(8-11-28)29-21-4-2-1-3-19(21)27-23(29)31/h1-6,13-14,17,26H,7-12H2,(H,25,30)(H,27,31) |
InChi Key | LHABRXRGDLASIH-UHFFFAOYSA-N |
Canonical SMILES | C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCNC(=O)C4=CC5=C(N4)C=CC(=C5)F |
Isomeric SMILES | C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCNC(=O)C4=CC5=C(N4)C=CC(=C5)F |
PubChem CID | 16739265 |
Molecular Weight | 421.48 |
PubChem CID | 16739265 |
---|---|
ChEMBL Ligand | CHEMBL398567 |
CAS Registry No. | 939055-18-2 |
Enter Lot Number to search for COA:
To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
A2219605 | Certificate of Analysis | May 26, 2022 | F340883 |
G2219599 | Certificate of Analysis | May 26, 2022 | F340883 |
G2219600 | Certificate of Analysis | May 26, 2022 | F340883 |
G2219601 | Certificate of Analysis | May 26, 2022 | F340883 |
G2219602 | Certificate of Analysis | May 26, 2022 | F340883 |
G2219603 | Certificate of Analysis | May 26, 2022 | F340883 |
Solubility | Soluble in 1:9 DMF:PBS(ph7.2) (~0.1 mg/ml), ethanol (~0.25 mg/ml), DMSO (~20 mg/ml), and DMF (~20 mg/ml). |
---|---|
Refractive Index | n20D~1.66 (Predicted) |
Melt Point(°C) | 295.54° C (Predicted) |
1. Scott SA, Selvy PE, Buck JR, Cho HP, Criswell TL, Thomas AL, Armstrong MD, Arteaga CL, Lindsley CW, Brown HA. (2009) Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness.. Nat Chem Biol, 5 (2): (108-17). [PMID:19136975] |